03.18.13
Biotron Laboratories has announced the publication of the study “A Randomized, Double-Blind, Clinical Study on the Safety and Tolerability of an Iron Multi-Amino Acid Chelate Preparation in Premenopausal Women” appearing online in Informa Healthcare’s Journal of Dietary Supplements, Feb 2013 (Vol 10., No 1:17-28) .
This peer-reviewed clinical trial serves to demonstrate in a statistically significant fashion that Biotron’s Iron Amino Acid Chelate (Ferractiv) is better tolerated than ferrous sulfate, the latter of which is among the most commonly used iron ingredients. Additional work by Biotron has shown Ferractiv to demonstrate high bioavailability in an extremely sensitive in vitro model of iron uptake in human intestinal cells, using molecular and immunological methods. Taken together, Ferractiv confers all the benefits of a real amino acid chelate: improved tolerability and increased bioavailability, validating Biotron’s methods.
For further information: http://informahealthcare.com/toc/jds/current
This peer-reviewed clinical trial serves to demonstrate in a statistically significant fashion that Biotron’s Iron Amino Acid Chelate (Ferractiv) is better tolerated than ferrous sulfate, the latter of which is among the most commonly used iron ingredients. Additional work by Biotron has shown Ferractiv to demonstrate high bioavailability in an extremely sensitive in vitro model of iron uptake in human intestinal cells, using molecular and immunological methods. Taken together, Ferractiv confers all the benefits of a real amino acid chelate: improved tolerability and increased bioavailability, validating Biotron’s methods.
For further information: http://informahealthcare.com/toc/jds/current